IDiyas

For the Inventor, By the Inventor

El Granada, CA, United States of America

Timothy S Heuer

USPTO Granted Patents = 12 


Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Location History:

  • El Granada, CA (US) (2010 - 2014)
  • Pacifica, CA (US) (2014)

Company Filing History:

goldMedal12 out of 173 
 
Exelixis, Inc.
 patents

Years Active: 2010-2014

Loading Chart...
Loading Chart...
12 patents (USPTO):Explore Patents
1. 8771942 - SCDs as modifiers of the p53 pathway and methods of use (2014-07-08),
2. 8758994 - CDK9 as modifier of the IGF pathway and methods of use (2014-06-24),
3. 8632962 - PLKS as modifiers of the beta catenin pathway and methods of use (2014-01-21),
4. 8481269 - PIK4CA as modifier of the Rac pathway and methods of use (2013-07-09),
5. 8273536 - Marks as modifers of the PTEN pathway and methods of use (2012-09-25),
6. 8105785 - Mylks as modifiers of branching morphogenesis and methods of use (2012-01-31),
7. 8067181 - MELKS as modifiers of the Rac pathway and methods of use (2011-11-29),
8. 7943302 - C20ORF23 as modifier of the IGFR pathway and methods of use (2011-05-17),
9. 7927872 - ALDOs as modifiers of the IGF pathway and methods of use (2011-04-19),
10. 7888048 - P4HAS as modifiers of the IGFR pathway and methods of use (2011-02-15),
11. 7888047 - PDEs as modifiers of the IGFR pathways and methods of use (2011-02-15),
12. 7785805 - MAN2As as modifiers of the IGFR pathway and methods of use (2010-08-31),

Title: Innovations and Contributions of Timothy S. Heuer

Introduction

Timothy S. Heuer is a prominent inventor based in El Granada, California. He has made significant contributions to the field of biotechnology, particularly in understanding the p53 and IGF pathways. With a total of 12 patents to his name, Heuer's work has the potential to impact therapeutic approaches for various disorders.

Latest Patents

Heuer's latest patents include groundbreaking research on SCDs as modifiers of the p53 pathway. This work identifies human SCD genes as modulators of the p53 pathway, presenting them as therapeutic targets for disorders associated with defective p53 function. Additionally, he has developed methods for identifying modulators of p53, which involve screening for agents that can modulate the activity of SCD. Another significant patent focuses on CDK9 as a modifier of the IGF pathway. This research identifies human CDK9 genes as modulators of the IGF pathway, making them potential therapeutic targets for disorders linked to defective IGF function. Heuer also provides methods for identifying modulators of IGF through screening for agents that can modulate the activity of CDK9.

Career Highlights

Heuer's career is marked by his innovative research and contributions to the scientific community. His work at Exelixis, Inc. has positioned him as a key figure in the biotechnology sector. His patents reflect a deep understanding of molecular biology and its applications in medicine.

Collaborations

Heuer has collaborated with notable colleagues, including Lynn Margaret Bjerke and Helen Louise Francis-Lang. These collaborations have further enriched his research and expanded the impact of his inventions.

Conclusion

Timothy S. Heuer's contributions to biotechnology through his patents and research are noteworthy. His work continues to pave the way for advancements in therapeutic strategies targeting critical biological pathways.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…